UBS Assumes Vertex Pharmaceuticals at Buy, Lowers Price Target of $535

Benzinga · 01/07 13:42
UBS analyst Michael Yee assumes Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy rating and lowers Price Target of $535.